{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:47:59Z","timestamp":1788234479361,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126309","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:44:23Z","timestamp":1725691463000},"page":"126309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial"],"prefix":"10.1016","volume":"42","author":[{"given":"Eckhardt","family":"Petri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibadas","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Folschweiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7446","key":"10.1016\/j.vaccine.2024.126309_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.126309_bb0010","year":"2024"},{"key":"10.1016\/j.vaccine.2024.126309_bb0015","series-title":"Latest data and information on infectious diseases and public health epidemiological bulletin \u2013 Increase in dengue fever cases in Germany in the first few months of 2024. Epidemiologisches Bulletin 20\u201321\/2024 (rki.de)","author":"Robert Koch Institute","year":"2024"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126309_bb0020","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Health Organ"},{"issue":"42","key":"10.1016\/j.vaccine.2024.126309_bb0025","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126309_bb0030","author":"European Medicines Agency"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126309_bb0035","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126309_bb0040","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/infdis\/jiv179","article-title":"Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blinded phase 1 clinical trial","volume":"212","author":"George","year":"2015","journal-title":"J Infect Dis"},{"issue":"27","key":"10.1016\/j.vaccine.2024.126309_bb0045","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1016\/j.vaccine.2018.05.028","article-title":"A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126309_bb0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10234","key":"10.1016\/j.vaccine.2024.126309_bb0055","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.vaccine.2024.126309_bb0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126309_bb0065","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126309_bb0070","doi-asserted-by":"crossref","first-page":"e1350","DOI":"10.1093\/cid\/ciac418","article-title":"Clinical safety experience of TAK-003 for dengue fever: a new tetravalent live attenuated vaccine candidate","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126309_bb0075","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2019.11.061","article-title":"Safety and immunogenicity of a single dose of a tetravalent dengue vaccine with two different serotype-2 potencies in adults in Singapore: a phase 2, double-blind, randomised, controlled trial","volume":"38","author":"Tricou","year":"2020","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2024.126309_bb0085","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126309_bb0090","author":"Australian Government Department of Health Therapeutic Goods Administration"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:41:28Z","timestamp":1741873288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":17,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X24009915"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126309","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Takeda Vaccines, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126309"}}